- Founded
- 2016
- Employees
- 75
- Total Funding
- $181.2M
Founded by Bill Haney, Kathleen McCarthy in 2016.
About Skyhawk Therapeutics
Skyhawk is committed to discovering, developing and commercializing small molecule therapeutics that modify RNA expression. We use our novel SkySTAR® platform (Skyhawk Small molecule Therapeutics for Alternative splicing of RNA) to develop drug candidates directed toward targets for some of the world’s most intractable diseases including neurological conditions, cancer, and traditionally “undruggable” targets.
Leadership at Skyhawk Therapeutics
The team at the top of the org chart.
Bill Haney
CEO & Chairman of the Board
52 reports
Terrance Connolly
Chief Operating Officer
5 reports
John McKeague
Senior Vice President Legal
Maggie Beaudoin
VP Of Finance
3 reports
Douglas V Faller
Chief Medical Officer
6 reports
Kyle Dow
Chief Financial Officer
Sergey Paushkin
Chief Scientific Officer
23 reports
Joseph Duffy
Executive Vice President Of Medicinal Chemistry And CMC
5 reports
Steven Taylor
Executive Vice President Business Development
1 report
Board
Adrian Krainer
Advisor
Ben Blencowe
Advisor
Ben Ebert
Advisor
Friedrich Metzger
Advisor
Frédéric Allain
Advisor
Jacqueline A. Lees
Advsior
Open Jobs at Skyhawk Therapeutics (2)
Similar companies hiring
Top employers in Biotechnology